Trial reportMediators of inflammation2013
Aged garlic extract improves adiponectin levels in subjects with metabolic syndrome: a double-blind, placebo-controlled, randomized, crossover study.
Trial report in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 69 citations in OpenAlex.
- Trial
- Effects of aged garlic extract may differ between normal cells and cancer cells.Biomedical reports · 2025Article
- Anti?atherosclerotic effect of aged garlic extract: Mode of action and therapeutic benefits (Review).Experimental and therapeutic medicine · 2025Review
- Aged garlic extract enhances the production of β‑defensin 4 via activation of the Wnt/β‑catenin pathway in mouse gingiva.Experimental and therapeutic medicine · 2025Article
- Understanding the prevalence, progression, and management of metabolic syndrome in Saudi Arabia.Saudi medical journal · 2023Review
- Article
- Therapeutic effect of aged garlic extract on gingivitis in dogs.Frontiers in veterinary science · 2023Article
- Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies.Frontiers in nutrition · 2023Review
- Metabolic syndrome; Definition, Pathogenesis, Elements, and the Effects of medicinal plants on it's elements.Journal of diabetes and metabolic disorders · 2022Review
- Black Garlic and Its Bioactive Compounds on Human Health Diseases: A Review.Molecules (Basel, Switzerland) · 2021Review
- Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges.Nutrients · 2021Review
- The Effect of Garlic (Clinical nutrition research · 2021Article
- Review
- Review
- Observational
- Article
- Potential Health Benefit of Garlic Based on Human Intervention Studies: A Brief Overview.Antioxidants (Basel, Switzerland) · 2020Review
- Beneficial Effects of an Aged Black Garlic Extract in the Metabolic and Vascular Alterations Induced by a High Fat/Sucrose Diet in Male Rats.Nutrients · 2019Article
- Safety and efficacy of aged garlic extract in dogs: upregulation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway and Nrf2-regulated phase II antioxidant enzymes.BMC veterinary research · 2018Article
- Association between Dietary Inflammatory Index and Metabolic Syndrome in the General Korean Population.Nutrients · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGarlic (Allium sativum) has been shown to have important benefits in individuals at high cardiovascular risk. The aim of the present study was to evaluate the effects of the administration of aged garlic extract (AGE) on the risk factors that constitute the cluster of metabolic syndrome (MS). METHODS AND
designDouble-blind, crossover, randomized, placebo-controlled clinical trial to assess the effect of 1.2 g/day of AGE (Kyolic), for 24 weeks of treatment (12 weeks of AGE and 12 weeks of placebo), on subjects with MS.
resultsThe administration of AGE increased the plasma levels of adiponectin (P = 0.027). No serious side effects associated with the intervention were reported.
conclusionThe present results have shown for the first time that the administration of AGE for 12 weeks increased plasma adiponectin levels in patients with MS. This suggests that AGE might be a useful, novel, nonpharmacological therapeutic intervention to increase adiponectin and to prevent cardiovascular (CV) complications in individuals with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.